EUVIMEDEUVIMED entdecken
Crossref

Homeostasis Model Assessment of β-Cell Function for Diagnosis of Insulinoma

Kálmán Bódis, Martin Schön, Laura Dauben, Miriam Wilker, Klaus Strassburger iD, Volker Burkart iD, Michael Roden iD, Karsten Müssig iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Kálmán Bódis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225 Düsseldo…. Hauptthemen laut MEDLINE: Insulinoma, Pancreatic Neoplasms, Insulin Resistance. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Diagnosis of insulinoma is based on different criteria from the 72-hour fasting test according to current guidelines (Endocrine Society [ES], European [ENETS], and North American [NANETS] Neuroendocrine Tumor Societies), including assessment of β-cell function by glucagon stimulation test.

Objective

This study tested whether the homeostasis model assessment of insulin secretion, including assessment of β-cell function, (HOMA-B) at the end of the fasting test provides comparable efficacy for insulinoma diagnosis.

Methods

In 104 patients with suspected insulinoma, 72-hour fasting tests were performed with frequent assessment of glucose, insulin, and C-peptide in venous blood. HOMA-B values using insulin and C-peptide were calculated at the end of the fasting test, as defined by the lowest glucose concentration from each participant.

Results

HOMA-B was more than 6.5-fold higher in patients with (n = 23) than in those without (n = 81) insulinoma (insulin and C-peptide; both P < .001). HOMA-B (cutoff using insulin >253 a.u. and C-peptide >270 a.u.) had a sensitivity of 0.96, 0.78 to 1.00, and a specificity of 0.96 or greater (≥0.89-0.99) for insulinoma diagnosis. ES and ENETS/NANETS criteria reached a diagnostic sensitivity of less than or equal to 0.96 (≤0.78-1.00) and ≤0.83 (≤0.61-0.95) as well as specificity of ≤0.85 (≤0.76-0.92) and less than or equal to 1.00 (≤0.96-1.00) for insulin, and C-peptide, respectively. Using insulin for HOMA-B, sensitivity tended to be higher compared to ENETS/NANETS criteria (P = .063) and specificity was higher compared to ES criteria using insulin and C-peptide (both P < .005).

Conclusion

HOMA-B, as calculated at the end of the fasting test employing defined cutoffs for insulin and C-peptide, provides excellent diagnostic efficacy, suggesting that it might represent an alternative and precise tool to diagnose insulinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InsulinomaPancreatic NeoplasmsInsulin ResistanceHumansC-PeptideBlood GlucoseInsulinGlucoseHomeostasisFasting

Stichwörter der Autor:innen

72-hour fasting testhomeostasis model assessmentinsulinomainsulinoma diagnosis

Substanzen

C-PeptideBlood GlucoseInsulinGlucose

Autor:innen und Institutionen

  • Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
  • German Center for Diabetes Research, Partner Düsseldorf, 85764 München-Neuherberg, Germany.
  • Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
  • Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
  • Department of Internal Medicine, Gastroenterology and Diabetology, Niels Stensen Hospitals, Franziskus Hospital Harderberg, 49124 Georgsmarienhütte, Germany.

ORCID-Profile: Klaus Strassburger, Volker Burkart, Michael Roden, Karsten Müssig

Zitieren

APA

Bódis, K., Schön, M., Dauben, L., Wilker, M., Strassburger, K., Burkart, V., Roden, M., & Müssig, K. (2024). Homeostasis Model Assessment of β-Cell Function for Diagnosis of Insulinoma. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad618

Vancouver

Bódis K, Schön M, Dauben L, Wilker M, Strassburger K, Burkart V, et al. Homeostasis Model Assessment of β-Cell Function for Diagnosis of Insulinoma. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad618

BibTeX
@article{Bdis2024,
  author = {Bódis, Kálmán and Schön, Martin and Dauben, Laura and Wilker, Miriam and Strassburger, Klaus and Burkart, Volker and Roden, Michael and Müssig, Karsten},
  title = {Homeostasis Model Assessment of β-Cell Function for Diagnosis of Insulinoma},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad618}
}
Kostenlos starten →